Why Adicet Bio, Inc.’s (ACET) Stock Is Down 6.42%
As of Friday, October 16, Adicet Bio, Inc.’s ACET share price has dipped by 6.42%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Commentary & Analysis
Why Adicet Bio, Inc.’s (ACET) Stock Is Down 5.97%
As of Tuesday, October 13, Adicet Bio, Inc.’s ACET share price has dipped by 5.97%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Adicet Bio, Inc.’s (ACET) Stock Is Down 6.15%
As of Thursday, October 08, Adicet Bio, Inc.’s ACET share price has dipped by 6.15%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Adicet Bio, Inc.’s (ACET) Stock Is Up 5.12%
As of Wednesday, September 30, Adicet Bio, Inc.’s ACET share price has surged by 5.12%, which has investors questioning if this is right time to sell.Michael Rose
Why Adicet Bio, Inc.’s (ACET) Stock Is Up 5.35%
As of Tuesday, September 29, Adicet Bio, Inc.’s ACET share price has surged by 5.35%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ACET | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $41.0 | $232.8 | 15% |
|
| Shares Out (Mil) | 10.7 | 53.4 | 22% |
|
| Institutional Ownership | 92.3% | 92.9% | 61% |
|
| Float (Mil) | 7.2 | 41.2 | 16% |
|
| Beta | 1.63 | 0.96 | 85% |
|
| Avg Daily Volume (000s) | 172 | 490 | 44% |
|
| Price Change (52-week) |
(73.6%) | 48.2% | 11% |
|
| Growth | ACET | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (26.1%) | (10.1%) | 16% |
|
| EPS (5yr) | 26.7% | 15.8% | 78 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.1%) | (15.7%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($1.578) | ($6.358) | ($4.040) | |
| Month Ago EPS | ($1.578) | ($6.358) | ($4.040) | |
| # Rev Up | 2 | 2 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($1.510) | ($8.800) | ($3.488) | |
| Year/Year Chg | (20.6%) | (62.5%) | (95.0%) | |
| Financials | ACET | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($99) | ($44) | 11% |
|
| EPS (TTM) | ($10.519) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($85) | ($33) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $2 | 39% |
|
| Long-Term Debt (Q1) (Mil) | $10 | $4 | 28% |
|
| Enterprise Value (Q1) (Mil) | ($62) | $174 | 1% |
|
| Valuation | ACET | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.34 | 2.22 | 6% |
|
| P/E | na | 20.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ACET | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (63.6%) | (47.3%) | 9% |
|
| ROE | (78.1%) | (53.3%) | 11% |
|
| Liabilities to Assets | 18.9% | 29.4% | 12% |
|
| F-Score | 1 | 2 | 1% |
|
Adicet Bio, Inc. did not pass any screens on 10/28/2026.
